OLD Second National Bank of Aurora Lowers Position in Pfizer Inc. (NYSE:PFE)

OLD Second National Bank of Aurora lessened its position in Pfizer Inc. (NYSE:PFE) by 41.7% in the fourth quarter, HoldingsChannel reports. The firm owned 4,985 shares of the biopharmaceutical company’s stock after selling 3,562 shares during the quarter. OLD Second National Bank of Aurora’s holdings in Pfizer were worth $144,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Worth Asset Management LLC purchased a new position in shares of Pfizer in the 1st quarter valued at approximately $29,000. Briaud Financial Planning Inc purchased a new position in Pfizer during the third quarter valued at $30,000. GoalVest Advisory LLC raised its stake in Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 811 shares during the last quarter. Mizuho Securities Co. Ltd. purchased a new position in Pfizer during the third quarter valued at $34,000. Finally, VisionPoint Advisory Group LLC raised its stake in Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 1,047 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

NYSE:PFE opened at $25.39 on Friday. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $143.74 billion, a P/E ratio of 70.51, a P/E/G ratio of 1.15 and a beta of 0.61. Pfizer Inc. has a 12 month low of $25.23 and a 12 month high of $40.56. The business’s 50-day moving average is $27.14 and its 200 day moving average is $28.74.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The firm had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company’s quarterly revenue was down 41.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.14 earnings per share. On average, equities research analysts forecast that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

Analyst Ratings Changes

PFE has been the subject of several recent analyst reports. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a research note on Thursday, January 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Monday. Guggenheim started coverage on Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective for the company. Finally, Argus lowered Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Twelve research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $36.88.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.